In 2014, Elmaagacli et al.
1 described a series of 20 patients with moderate/severe steroid-refractory or intolerant chronic GvHD treated with a urinary-derived preparation of human chorionic gonadotropin (hCG), given as an immune modulator based on its known tolerizing effects during pregnancy. 2 The hCG treatment was given as a low-dose (187.5 IU) daily SC injection and was well tolerated. Remarkably, in this series of heavily pre-treated patients with chronic GvHD (that is, the median number of prior therapies for chronic GvHD in this cohort was 4), 60% of patients showed an objective response after 8 weeks of hCG therapy. One of the most marked examples of response to therapy was a patient with severe gastrointestinal GvHD who demonstrated healing of diffusely inflamed colonic epithelium after treatment with hCG. Correlative studies indicated a sevenfold increase in peripheral blood mononuclear cell expression of indoleamine 2,3 dioxygenase and a doubling of serum interleukin-10 levels during the study. One patient underwent a longitudinal study of circulating regulatory T cells (Treg), and expansion of the Treg pool was noted with hCG treatment.
Although this study represents a shift away from immunosuppression towards induction of tolerance-a welcome paradigm shift-in the therapy of refractory GvHD, further studies are needed. For example, pharmacokinetics and pharmacodynamics studies should be performed to determine the optimal dosage to achieve the desired immunologic effects of hCG. Perhaps even more importantly, the contribution of the non-hCG constituents of the preparations should be assessed for their role in achieving responses. Urinary-derived preparations of hCG are not purified, isolated hormone. They contain biologically relevant concentrations of a number of immune modulatory cytokines and growth factors in addition to hCG. For example, we have identified high concentrations of epidermal growth factor (EGF) and several other growth factors, cytokines and chemokines in a commercially available preparation of urinary-derived hCG (Pregnyl, Merck, Kenilworth, NJ, USA) using a 38-multiplex cytokine array (Millipore, Billerica, MA, USA) on a Luminex instrument (Austin, TX, USA) in the University of Minnesota Cytokine Reference Laboratory ( Table 1) . The sample from a single lot was tested in duplicate. The urinaryderived preparation used in the Elmaagacli study (Choragon, Ferring, Kiel, Germany) is not available for clinical use in the United States. However, that preparation has been shown in a prior study to have a similarly high EGF content compared with Pregnyl when tested via a specific EGF immunoassay. 3 To our knowledge, measurement of other immunoregulatory proteins using a multiplex cytokine array has not been performed on these preparations.
High concentrations of EGF, in particular, could be advantageous as a supplement in refractory GvHD. We have recently identified that circulating EGF is markedly lower in patients with GvHD compared with allogeneic hematopoietic cell transplant (HCT) recipients without GvHD. 4 Furthermore, in patients with GvHD who do not respond to first-line therapy with corticosteroids, plasma EGF levels significantly decline from a median of 20 pg/mL down to 7 pg/mL after 28 days from the onset of GvHD, compared with a median plasma EGF of 141.4 pg/mL in allogeneic HCT recipients who did not develop GvHD. 4 Consequently, in patients with refractory GvHD, circulating EGF levels are only 5% of normal post-allogeneic HCT levels, suggesting that a significant EGF deficiency state may be present in these patients.
We have recently shown that both allogeneic HCT (without GvHD) and normal first trimester pregnancy are two settings where markedly high circulating levels of EGF are encountered. 4, 5 With elevated EGF levels during pregnancy, it is no surprise that EGF can be found in high concentrations in urinary hCG preparations. It is possible that the hCG given in the study described by Elmaagacli et al.
1 also provided a significant EGF supplement that could aid in wound healing. In order to clarify the role of hCG versus the biologically active, and other potentially desirable constituents of the product, such as EGF, a study comparing recombinant hCG versus urinary-derived preparations could be performed. With the potential for preparation and lot-tolot variability, the specific dose of EGF contained within individual vials of hCG could be determined before administration. In doing so, the pharmacokinetics of EGF supplementation could be better estimated. As EGF is not currently available to give as a standalone parenteral supplement, this type of study may be a practical way to further examine the potential relationship between EGF and wound healing in steroid-refractory GvHD. These types of studies are critically important as we re-evaluate the current treatment paradigm of refractory GvHD. It may be possible to repurpose these hormones as a widely available, inexpensive and safe immune modulatory adjunctive therapy to induce tolerance and support wound healing in refractory GvHD. In the current clinical care of patients, we hope that these two key aspects of recovery from severe GvHD-immunologic tolerance and wound healing-occur spontaneously after treatment of inflammation. The very poor outcomes with current therapies for refractory GvHD suggests that rather than merely hoping for endogenous healing processes to initiate after intensification of immunosuppression, we should instead be seeking adjunctive 
